The Chemours Company (CC) Company Overview

What does The Chemours Company do?

The Chemours Company is a global performance-chemicals producer created through the 2015 separation from DuPont. It sells materials that are usually invisible to the end consumer but critical to refrigeration, air conditioning, coatings, plastics, semiconductors, transportation, energy systems and industrial equipment. Its portfolio is organized around Thermal & Specialized Solutions, Titanium Technologies and Advanced Performance Materials. The company describes these businesses and their flagship brands on its official business portfolio page.

Where does Chemours sit in the industrial value chain?

Chemours is an upstream and intermediate materials supplier rather than a finished-goods manufacturer. Customers incorporate its molecules, pigments and engineered materials into products such as low-global-warming-potential cooling systems, white architectural coatings, high-purity semiconductor components and harsh-environment seals. This position creates recurring technical demand, but it also exposes Chemours to customer inventory cycles, plant utilization, raw-material costs and regulation.

How does Chemours make money, and which segment matters most?

Chemours earns revenue by manufacturing and selling chemical products under multi-year customer relationships, distributor arrangements and spot or formula-based pricing. Profit is not determined by revenue alone. Product mix, utilization, ore and feedstock costs, seasonal refrigerant demand, currency and the timing of customer inventory restocking can move segment EBITDA sharply.

Why is TSS the current earnings engine?

TSS benefits from the transition toward lower-global-warming-potential refrigerants. In FY2025, Opteon adoption lifted both volume and price, creating a much stronger margin profile than the company’s other segments. The strategic tension is that this attractive regulatory transition must offset weaker titanium dioxide economics, volatile R32 input costs and execution issues in APM.

What do Chemours’ latest results show?

The latest official reporting package is the quarter ended March 31, 2026. Chemours reported Q1 2026 net sales of $1.381 billion, up 1% year over year, but a GAAP net loss of $29 million. Adjusted EBITDA rose 2% to $169 million because strong TSS pricing and mix offset much weaker performance in TT and APM. The full release is available in the company’s Q1 2026 results announcement, with the detailed filing in the March 31, 2026 Form 10-Q.

Which business carried the quarter?

Which strategic turning points still shape Chemours today?

Chemours’ current economics are best understood as the product of a separation, a rapid early restructuring, a portfolio refocus and a continuing attempt to convert legacy fluorochemical capabilities into growth platforms. The company’s official history provides the operating context behind these changes.

1. 2015
   Chemours separated from DuPont and began trading independently. The transaction created a focused chemical company but also left substantial debt and legacy environmental exposure.
2. 2016
   Management sold non-core businesses and paid down $150M of debt, establishing cost reduction and balance-sheet repair as core disciplines.
3. 2017
   Completion of the early transformation supported a fivefold quarterly dividend increase and a $500M repurchase authorization, showing confidence after the initial turnaround.
4. 2020
   The Chemours Discovery Hub opened, concentrating U.S. research capabilities and strengthening application development around differentiated materials.
5. 2021
   The former Fluoroproducts segment was divided into TSS and APM, making refrigerant transition economics more visible and separating them from specialty-material applications.
6. 2025
   The Pathway to Thrive strategy emphasized cash generation, cost reduction, portfolio quality and a long-term net leverage target below 3x through the cycle.
7. 2026
   Chemours began monetizing the former Kuan Yin site and directed proceeds toward debt reduction, reinforcing balance-sheet repair as a strategic priority.

What did the Kuan Yin transaction change?

Chemours announced approximately $360 million of expected gross proceeds from the former Taiwan titanium dioxide site. By April 2026, nine parcels had closed for approximately $287 million of net cash proceeds, and Chemours used part of the proceeds plus cash on hand to repay €140 million of term loans. The official Kuan Yin sale announcement shows how non-operating assets are being converted into deleveraging capacity.

What gives Chemours a competitive advantage?

Chemours’ strongest resources are process know-how, globally recognized brands, customer qualifications, application engineering and scale in selected chemistries. These advantages are uneven across the portfolio. TSS currently combines regulation-driven demand with differentiated intellectual property and manufacturing expertise. TT has scale and Ti-Pure brand recognition, but the pigment market remains exposed to global oversupply and price competition. APM has demanding qualifications in semiconductors, membranes, seals and lubricants, yet plant reliability is essential to monetizing that technical position.

Who are Chemours’ main competitors?

Competition differs by chemistry. In premium titanium dioxide pigment, Chemours’ 2025 Form 10-K names Tronox, LB Group, Kronos Worldwide and INEOS. Refrigerants compete against other global fluorochemical producers and substitute technologies, while APM competes against diversified specialty-material companies and customer-specific alternatives. The relevant question is not whether Chemours has competitors; it is whether technical performance, reliability and customer qualification permit price and mix to outrun cost inflation.

How financially strong is Chemours through the cycle?

Chemours has enough liquidity to operate and invest, but leverage limits strategic flexibility. At March 31, 2026, total liquidity was approximately $1.5 billion, including $563 million of unrestricted cash and $953 million of revolving capacity net of letters of credit. Net leverage was approximately 4.9x trailing adjusted EBITDA, well above management’s stated long-term goal of below 3x across economic cycles.

How should margin and cash flow be interpreted?

The Q1 2026 consolidated gross margin was approximately 15.4%, calculated from $212 million of gross profit divided by $1.381 billion of net sales. That was below the approximately 17.3% margin in Q1 2025. Free cash flow equals operating cash flow minus capital expenditures; on that basis, Q1 2026 free cash flow was negative $93 million, but improved by $103 million from Q1 2025 as working-capital usage and capital spending declined.

Who owns Chemours stock, and what does governance signal?

Chemours has a single common share class, and each outstanding share has one vote. The investor base is dispersed rather than founder-controlled. According to the 2026 proxy statement, BlackRock beneficially owned 16.81% and Vanguard 11.76% as of the disclosed dates used in the filing. Directors, nominees and executive officers as a group beneficially owned 1,280,383 shares, representing less than 1% of the class as of March 2, 2026.

How are management incentives aligned?

The 2025 annual incentive framework placed 50% weight on adjusted EBITDA, 20% on corporate-function cost, 10% on discretionary free cash flow, 10% on trailing-twelve-month cash conversion cycle and 10% on executive KPIs. This is a revealing scorecard: management is explicitly measured on earnings, cost discipline, cash conversion and safety-related execution rather than pure revenue growth.

What opportunities could improve Chemours’ earnings mix?

The clearest opportunity is continued adoption of Opteon refrigerants as automotive and stationary systems shift toward lower-global-warming-potential solutions. Q1 2026 Opteon sales reached $313 million, up 12% year over year, while Freon sales reached $162 million, up 67%. TSS can also expand through data-center thermal management, specialty fluids and foam applications.

Can APM become a second specialty-growth engine?

APM’s opportunity is tied to semiconductor fabrication, advanced electronics, clean energy, hydrogen-related membranes, high-performance transportation and industrial reliability. The segment’s Q1 2026 sales were only $243 million because the Washington Works outage and portfolio exit constrained volume. A normalized plant run-rate, higher-purity product adoption and better mix could restore earnings faster than revenue alone suggests.

What risks could weaken the Chemours story?

Chemours faces the usual industrial risks of demand cycles, raw-material costs, plant reliability and competition, but its most distinctive risk is the interaction between fluorochemical regulation and legacy environmental liabilities. In June 2026, Chemours announced an agreement with the U.S. EPA and West Virginia regulators covering PFAS-related claims at three operating sites. The company expects a $22.5 million civil penalty over three years and $90 million of additional mitigation projects over 15 years. The terms are described in the company’s June 2026 PFAS settlement announcement and related Form 8-K.

Which risk is most financially material?

Legacy liabilities are difficult because they can create cash outflows and accounting charges outside normal product economics. FY2025 included substantial litigation-related charges, contributing to a $386 million GAAP net loss despite $742 million of adjusted EBITDA. The gap between GAAP and adjusted results is therefore not a technical footnote; it is a core part of the company’s valuation and liquidity analysis.

Which KPIs matter most for a Chemours valuation?

A discounted cash flow model should not begin with a single consolidated growth rate. Chemours is a portfolio of businesses with different margin structures and cycles. The most useful forecast separates TSS transition growth, TT price-volume recovery and APM normalization, then reconciles those operating forecasts to working capital, capital expenditures, interest, taxes and environmental cash costs.

What should researchers monitor next?

The company’s FY2025 business, risk and financial disclosures are available in its 2025 Form 10-K. That filing is the appropriate baseline for a segment-level DCF because it connects product markets, facilities, competition, liabilities and annual cash flows.

What is the key takeaway from Chemours analysis?

Chemours is important because it sits at the intersection of essential industrial chemistry and environmental transition. Its refrigerants, pigments and advanced materials enable cooling, coatings, electronics, transportation and energy applications that are difficult to replace quickly. The company also illustrates a classic strategy problem: a differentiated specialty portfolio can coexist with cyclical commodity exposure, high fixed costs, leverage and legacy liabilities.

The strongest part of the current story is TSS. FY2025 segment sales reached $2.1 billion and adjusted EBITDA reached $670 million, while Q1 2026 margin reached 33%. The principal improvement path is broader earnings participation from TT and APM, better working-capital conversion and debt reduction. The principal weakness is that environmental and litigation obligations can absorb cash even when adjusted operating performance appears healthy.